Shionogi Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$46.8M
Doctors Paid
14,459
Transactions
45,482
2024 Total
$1.7M
Payment Breakdown by Category
Research$39.2M (83.8%)
Consulting$3.8M (8.2%)
Food & Beverage$924,739 (2.0%)
Travel$632,110 (1.4%)
Royalty/License$49,800 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39.2M | 6,659 | 83.8% |
| Consulting Fee | $3.8M | 1,155 | 8.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1.3M | 430 | 2.8% |
| Food and Beverage | $924,739 | 34,476 | 2.0% |
| Travel and Lodging | $632,110 | 1,653 | 1.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $507,040 | 185 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $204,778 | 115 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $83,050 | 41 | 0.2% |
| Royalty or License | $49,800 | 4 | 0.1% |
| Grant | $33,729 | 2 | 0.1% |
| Education | $15,149 | 762 | 0.0% |
Payments by Type
Research
$39.2M
6,659 transactions
General
$7.6M
38,823 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications CAPSTONE 2 | $15.7M | 0 | 3,645 |
| A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza CAPSTONE 1 | $6.9M | 0 | 1,309 |
| Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause | $5.3M | 0 | 792 |
| Evaluation of S-600918 in Adults With Refractory Chronic Cough | $1.6M | 0 | 216 |
| Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults | $1.4M | 0 | 10 |
| Assessment of the In Vivo Efficacy of Cefiderocol against Gram-Negative Bacteria under iron-depleted and iron-overloaded conditions in the Neutropenic Murine Thigh infection model | $1.2M | 0 | 27 |
| MAD Study | $728,958 | 0 | 4 |
| Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens APEKS-NP | $633,442 | 0 | 196 |
| DDI P-gpBCRP Study | $607,646 | 0 | 4 |
| Demonstrate in pre-clinical model S18-003575 is suitable as a HSV-2 therapeutic vaccine equivalent | $589,549 | 0 | 2 |
| DDI UGT Study | $555,583 | 0 | 5 |
| Hepatic Impairment Study | $531,937 | 0 | 4 |
| Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures L-PLUS 2 | $397,469 | 0 | 125 |
| In Vivo Efficacy of Cefiderocol Alone and in Combination with Meropenem, Ceftazidime/Avibactam or Tigecycline against Acinetobacter baumannii in the Neutropenic Murine Thigh Infection Model | $304,603 | 0 | 5 |
| Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens CREDIBLE - CR | $295,139 | 0 | 78 |
| A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe | $267,149 | 0 | 30 |
| Effect of Continuous Renal Replacement Therapy and Residual Renal Clearance on Cefiderocol Pharmacokinetics in Critically Ill Adult Patients | $223,721 | 0 | 4 |
| DDI | $213,709 | 0 | 8 |
| Chronic cough Phase 1Phase 2 study | $213,089 | 0 | 1 |
| Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia | $198,651 | 0 | 26 |
| Population Pharmacokinetics of Cefiderocol during Acute Pulmonary Exacerbations in Adult Patients with Cystic Fibrosis | $184,437 | 0 | 5 |
| An Open-label Study With a Nonrandomized Single-dose Phase in Subjects With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections Followed by a Randomized, Multiple-dose, Active-controlled Phase in Subjects With Suspected or Confirmed Complicated Urinary Tract Infection (cUTI), to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Subjects 3 Months to < 18 Years of Age | $121,431 | 0 | 45 |
| Ex vivo Sequestration and Pharmacokinetics of Cefiderocol in Critically ill patients receiving Extracorporeal membrane oxygenation (ECMO)e | $103,130 | 0 | 4 |
| In Vitro Activity of Cefiderocol against a Contemporary, Global Collection of Carbapenem-Resistant Pseudomonas aeruginosa with a High Level of Carbapenemase Diversity | $76,179 | 0 | 2 |
| A Study to Characterize Metabolism, Excretion, and Mass Balance of S-649266 after Intravenous Administration of a 1000 mg 100 Ci Dose of 14C S 649266 in Healthy Adult Male Subjects | $75,678 | 0 | 3 |
| SRA202103-0008 | $75,003 | 0 | 2 |
| Molecular mechanisms of cefiderocol resistance in Acinetobacter baumannii | $70,701 | 0 | 1 |
| Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens (APEKS-NP) | $68,299 | 0 | 15 |
| TQT Study | $61,800 | 0 | 2 |
| S-004992-EF-027-N | $59,274 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Ellie Goldstein, M.d, M.D | Infectious Disease | Santa Monica, CA | $49,118 | $0 |
| Dr. Robert Bonomo, Md, MD | Infectious Disease | Cleveland, OH | $47,220 | $0 |
| Mr. Martin Gnoni, Md, MD | Student in an Organized Health Care Education/Training Program | Louisville, KY | $45,743 | $0 |
| Unknown Provider | — | — | $45,140 | $0 |
| Ramzy Rimawi, M.d, M.D | Infectious Disease | Atlanta, GA | $44,710 | $0 |
| Dr. Robert Brown, Md, MD | Hepatology | New York, NY | $44,244 | $0 |
| Johannes Van Den Anker, Md, MD | Neonatal-Perinatal Medicine | Washington, DC | $43,150 | $0 |
| Dr. Cornelius Clancy, Md, MD | Infectious Disease | Gainesville, FL | $43,080 | $0 |
| Dr. Yohei Doi, M.d, M.D | Infectious Disease | Pittsburgh, PA | $42,002 | $0 |
| Dr. Michael Satlin, M.d, M.D | Internal Medicine | New York, NY | $39,510 | $0 |
| Dr. Brandon Smith, Md, Pharmd, MD, PHARMD | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $36,468 | $0 |
| Hector Brunet Rodriguez, Md, MD | Student in an Organized Health Care Education/Training Program | Shreveport, LA | $35,231 | $0 |
| Dr. Thomas File, Md, MD | Infectious Disease | Akron, OH | $33,349 | $0 |
| Dr. Howard Williamson, Md, MD | Obstetrics & Gynecology | Cullman, AL | $32,731 | $0 |
| Christopher Cooper, Md, MD | Infectious Disease | Altamonte Springs, FL | $32,576 | $0 |
| Paul Auwaerter, M.d, M.D | Infectious Disease | Lutherville, MD | $31,049 | $0 |
| Irwin Goldstein, Md, MD | Urology | San Diego, CA | $30,563 | $0 |
| Dr. Andrew Kaunitz, M.d, M.D | Obstetrics & Gynecology | Jacksonville, FL | $30,000 | $0 |
| Keith Kaye, M.d, M.D | Internal Medicine | Ann Arbor, MI | $27,087 | $0 |
| Dr. Scott Beegle, M.d, M.D | Internal Medicine | Albany, NY | $26,471 | $0 |
| John Bradley, M.d, M.D | Pediatrics | San Diego, CA | $26,017 | $0 |
| Paul Kwo, M.d, M.D | Gastroenterology | Stanford, CA | $25,955 | $0 |
| Deepthi Jayasekara, Md, MD | Infectious Disease | Claremont, CA | $25,376 | $0 |
| Pierre Gholam, Md, MD | Gastroenterology | Cleveland, OH | $25,359 | $0 |
| Dr. Jagadeesh Reddy, M.d, M.D | Internal Medicine | Laguna Beach, CA | $25,151 | $0 |
Ad
Top Products
- Xofluza $9.5M
- Fetroja $6.0M
Associated Products (7)
Payment Categories
- Food & Beverage $924,739
- Consulting $3.8M
- Travel & Lodging $632,110
- Research $39.2M
- Royalties $49,800
About Shionogi Inc
Shionogi Inc has made $46.8M in payments to 14,459 healthcare providers, recorded across 45,482 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is Xofluza ($9.5M).
Payments were distributed across 164 medical specialties. The top specialty by payment amount is Infectious Disease ($2.1M to 1,051 doctors).
Payment categories include: Food & Beverage ($924,739), Consulting ($3.8M), Research ($39.2M), Travel & Lodging ($632,110), Royalties ($49,800).
Shionogi Inc is associated with 7 products in the CMS Open Payments database, including Xofluza, Osphena, and Fetroja.